רופרון -אי 4.5 מ.י./0.5 מ"ל

País: Israel

Idioma: hebreu

Font: Ministry of Health

ingredients actius:

INTERFERON ALFA 2A 4.5 MIU / 0.5 ML

Disponible des:

ROCHE PHARMACEUTICALS (ISRAEL) LTD

Codi ATC:

L03AB04

formulario farmacéutico:

SOLUTION FOR INJECTION

Vía de administración:

S.C

Fabricat per:

HOFFMANN LA ROCHE, SWITZERLAND

Grupo terapéutico:

INTERFERON ALFA-2A

indicaciones terapéuticas:

Roferon-A is indicated for the treatment of:- Condylomata acuminata - Hairy cell leukaemia.- AIDS patients with progressive, asymptomatic Kaposi's sarcoma who have a CD4 count > 250/mm3.- Chronic phase Philadelphia-chromosome positive chronic myelogenous leukaemia. Roferon-A is not an alternative treatment for CML patients who have an HLA-identical relative and for whom allogeneic bone marrow transplantation is planned or possible in the immediate future. It is still unknown whether Roferon-A can be considered as a treatment with a curative potential in this indication.- Adult patients with histologically proven chronic hepatitis B who have markers for viral replication, i.e., those who are positive for HBV DNA or HBeAg.- Adult patients with histologically proven chronic hepatitis C who are positive for HCV antibodies or HCV RNA and have elevated serum alanine aminotransferase (ALT) without liver decompensation.- Follicular non-Hodgkin’s lymphoma.- Advanced renal cell carcinoma.- Patients with AJCC stage II m

Data d'autorització:

2012-12-01